Stoke Therapeutics, Inc. STOK

What this company does

Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, the company develops antisense oligonucleotides to selectively restore protein levels. As of December 31, 2025, the company had 170 employees, 49 of whom hold an M.D. or Ph.D. Zorevunersen (STK-001), the company's first investigational medicine in development, is in late-stage clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. STK-002, the company's second product candidate, is a potential disease modifying therapy for the treatment of autosomal dominant optic atrophy, in an ongoing Phase 1 study. The company has a collaboration for the development and commercialization of zorevunersen outside of the United States, Canada, and Mexico, referred to as the Biogen Territory. Stoke Therapeutics, Inc. was founded in June 2014 and was incorporated under the laws of the State of Delaware. Its principal executive offices are located at 45 Wiggins Ave, Bedford, Massachusetts.

Written from the business description in Stoke Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.